GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (LTS:0OB3) » Definitions » Institutional Ownership

Valneva SE (LTS:0OB3) Institutional Ownership : 10.61% (As of Jun. 06, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Valneva SE Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Valneva SE's institutional ownership is 10.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Valneva SE's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Valneva SE's Float Percentage Of Total Shares Outstanding is 87.50%.


Valneva SE Institutional Ownership Historical Data

The historical data trend for Valneva SE's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Institutional Ownership Chart

Valneva SE Historical Data

The historical data trend for Valneva SE can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 10.86 10.90 10.78 10.93 10.59 10.62 10.58 10.61 10.67 10.61

Valneva SE Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Valneva SE (LTS:0OB3) Business Description

Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.

Valneva SE (LTS:0OB3) Headlines

No Headlines